Controlling Cholesterol: FDA approves Nexletol- FIRST once daily, non-statin treatment for familial hypercholesterolemia
It is the first oral, once-daily, Non-Statin LDL-Cholesterol lowering medicine approved in the U.S. in nearly 20 Years for indicated patients.;
US: Food and Drug Administration has approved Bempedoic acid (NEXLETOL)—a once-daily, oral non-statin treatment for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD), as an adjunct to diet and maximally tolerated statin therapy.
It is the first oral, once-daily, Non-Statin LDL-Cholesterol lowering medicine approved in the U.S. in nearly 20 Years for indicated patients. It lowers LDL-cholesterol with a first-in-class mechanism and fills an unmet need for affordable medicines for millions of patients with ASCVD or HeFH.Nexletol will be commercially available after March 2020.
The approval of NEXLETOL is supported by a global pivotal Phase 3 LDL-C lowering program conducted in more than 3,000 patients. In these studies, NEXLETOL provided an average of 18 per cent placebo corrected LDL-C lowering when used with moderate or high-intensity statins. Results from the Phase 3 development program have been published in The New England Journal of Medicine (040 Study), and The Journal of the American Medical Association (047 Study).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.